pharma · Ventilator-Associated Pneumonia · Carcinoma, Squamous Cell
Janssen Research &
Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
Johnson & Johnson is a pharma organization headquartered in CN. Primary therapeutic focus areas include Ventilator-Associated Pneumonia, Carcinoma, Squamous Cell, Erectile Dysfunction, Schizoaffective Disorder, Acute Cor
Raritan, USA HQ
2001 Founded
95 Employees
NMPA registrant Type
Company details
- Status
- Public
- HQ
- Raritan, USA
- Founded
- 2001
- Employees
- 95
- Programs
- 7
- Drugs
- 4
- Patents
- 0
Doripenem
Phase 3 · small molecule · Ventilator-Associated Pneumonia
Doripenem for Ventilator-Associated Pneumonia is a Phase 3 program (small_molecule) at Johnson & Johnson Pharmaceutical Research & Development, L.L.C. with 1 ClinicalTrials.gov record(s).
Internal code CR014038
Full intelligence profile for this program is being prepared.
At a glance
- Sponsor
- Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
- Phase
- Phase 3
- Modality
- small_molecule
- Indication
- Ventilator-Associated Pneumonia
- Status
- terminated
- Trials
- 1